Browse treatments

…ctivity of cICs was significantly reduced in CTD patients after CD19-CAR T-cell therapy.Conclusions Our study reveals the presence of Fc-gamma-R-engagi…

…3.1, respectively ( table 1).82.1% of SSc-ILD patients recieved corticosteroids, and 48.7% recieved antimalarials. Mycophenolate mofetil, ritux…

…h progressive disease according to ATS/ERS criteria.Patients on corticosteroid therapy at doses higher than 10 mg/day of prednisone(or equivalent),wit…

…f unavailable, then by echocardiographic criteria combined with PAH-specific treatment. Disease duration was stratified as early (<7 years) or late (>…

…pertension and 32.55% dyslipidemia, all of them controlled with medication. No patient had diabetes. One patient is an active smoker, and …

…nal involvement, SSc subtypes, anti-Scl-70 antibodies, DMARD or vasodilator treatment did not reach statistical significance.Conclusions Global morta…

…osuppression (intravenous methylprednisolone and rituximab) and cardioprotective treatment she developed acute cardiogenic shock, necessitated ICU admissi…

…), weight loss (49%), constipation (47%), and flatulence (26%). Parenteral nutrition was required in 21%.The median delay from gastrointestinal symp…

… multi-organ involvement. Management relies on vasodilators and immunosuppressive therapy, with prognosis determined by internal organ disease severity.M…

…y endpoint (onset of a digital ulcers (DU) and/or escalation of vasoactive therapy). In secondary Cox regression analyses each component of the co…

…nd we have observed S&P in SSc patients triggered by trauma and vaccination, hinting the potential role of aberrant immunity in S&P pathoge…

…and >15). We recorded the presence of PAH, DU and CC and use of vasodilator therapies. Patient and clinician reported questionnaires were completed.P…